Drug intelligence / Profile preview

ciprofloxacin + doxycycline

Development stage
Phase 1
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

**Ciprofloxacin + doxycycline** is a combination of two antibiotics, **ciprofloxacin** (a fluoroquinolone) and **doxycycline** (a tetracycline), used together as a prophylactic or therapeutic regimen for bacterial infections, including infection prevention in neutropenic patients post-autologous stem cell transplant for multiple myeloma, and has been studied for potential use in other serious or resistant bacterial infections. - **Ciprofloxacin** acts by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively preventing DNA replication and transcription. - **Doxycycline** inhibits the 30S ribosomal subunit, thereby blocking protein synthesis in bacteria. This combination has shown to be effective in reducing infection rates when compared to ciprofloxacin alone in specific high-risk patient populations[1]. The synergistic or suppressive interplay between their mechanisms may also affect bacterial resistance patterns[4]. No well-established brand name exists for this exact fixed combination, and the regimen typically involves co-administration of the individual drugs.

02

Targets

Bacterial RibosomeDNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on ciprofloxacin + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + doxycycline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call